Assembly Biosciences, Inc. (ASMB)
| Market Cap | 479.08M +144.9% |
| Revenue (ttm) | 74.85M +125.1% |
| Net Income | -42,000 |
| EPS | -0.00 |
| Shares Out | 20.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 170,465 |
| Open | 23.00 |
| Previous Close | 22.82 |
| Day's Range | 22.72 - 23.58 |
| 52-Week Range | 21.80 - 39.71 |
| Beta | 1.16 |
| Analysts | Strong Buy |
| Price Target | 52.00 (+120.99%) |
| Est. Earnings | Nov 9, 2026 |
About ASMB
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next g... [Read more]
Financial Performance
In 2025, Assembly Biosciences's revenue was $72.30 million, an increase of 153.52% compared to the previous year's $28.52 million. Losses were -$6.12 million, -84.76% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ASMB stock is "Strong Buy." The 12-month stock price target is $52.0, which is an increase of 120.99% from the latest price.
News
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction
Assembly Biosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Multiple antiviral programs are advancing, with key phase II studies for HDV and cholestatic liver diseases planned through 2027. Strategic collaboration with Gilead provides significant milestone and royalty potential, while a strong cash position supports ongoing development and pipeline expansion.
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver ...
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –
Assembly Biosciences Slides: Corporate presentation
Assembly Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on September 4, 2026.
Assembly Biosciences price target raised to $53 from $45 at Mizuho
Mizuho analyst Salim Syed raised the firm’s price target on Assembly Biosciences (ASMB) to $53 from $45 and keeps an Outperform rating on the shares. The firm updated the company’s…
Assembly Biosciences initiated with a Buy at UBS
UBS initiated coverage of Assembly Biosciences (ASMB) with a Buy rating and $52 price target The company has a “de-risked” antiviral platform, anchored by Gilead’s development of the herpes simplex…
Assembly Biosciences reports Q2 EPS (20c), consensus (52c)
Reports Q2 revenue $13.37M, consensus $6.45M. “During the second quarter, we advanced several important strategic priorities, including expanding ABI-6250 into cholestatic liver diseases and strengthe...
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) –
Assembly Biosciences Quarterly report: Q2 2026
Assembly Biosciences has published its Q2 2026 quarterly earnings report on August 13, 2026.
Assembly Biosciences Earnings release: Q2 2026
Assembly Biosciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Assembly Biosciences Slides: Corporate presentation
Assembly Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Assembly Biosciences price target raised to $45 from $40 at Mizuho
Mizuho raised the firm’s price target on Assembly Biosciences (ASMB) to $45 from $40 and keeps an Outperform rating on the shares. The firm updated the company’s model post the…
Assembly Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing HSV-2 and liver disease programs, with strong phase I data and a key partnership accelerating HSV-2 development. Upcoming milestones include a profit-share decision, phase II data for HSV-2 and hep delta, and expansion into cholestatic liver diseases.
Assembly Biosciences Transcript: AGM 2026
The meeting covered board elections, executive compensation, auditor ratification, and amendments to incentive and stock purchase plans. All proposals passed with a quorum present, and no questions were raised by shareholders.
Assembly Biosciences Transcript: Jefferies Global Healthcare Conference 2026
Multiple clinical programs are advancing, with key catalysts expected for HSV and hepatitis delta. ABI-6250 is expanding into PBC and PSC, with Phase II trials and data on the horizon. Financial runway extends into 2028, and partnering discussions for hepatitis B assets are ongoing.
Assembly Biosciences Announces Upcoming Investor Conference Presentations
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver di...
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver di...
Assembly Biosciences announces expansion of ABI-6250 clinical development
Assembly Biosciences (ASMB) announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatitis delta virus infection, into primary biliary cholang...
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver di...
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 – – Builds on completed Phase 1a study and ongoing development in HDV –
Assembly Biosciences Transcript: Bank of America Global Healthcare Conference 2026
The discussion highlighted progress in advancing antiviral candidates for HSV and hepatitis D, with strong early clinical data and strategic partnerships driving pipeline momentum. Oral therapies aim to address unmet needs in efficacy, convenience, and transmission, with key data readouts expected by 2027.
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, to...
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, to...
Assembly Biosciences reports Q1 EPS (54c), consensus (64c)
Reports Q1 revenue $8.21M, consensus $6.95M. “The first quarter reflected steady progress across our portfolio as we continue advancing our discovery and development programs,” said Jason Okazaki, chi...